The Quantellect read.As of Nov 19, 2026, 3 active firms cover Sana Biotechnology Inc: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $6.00 to $7.00, so the covering firms are broadly aligned. The average target of $6.67 sits 259% above the current $1.85. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.10 next quarter toward $-0.44 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$6.67
+259.4% upside
Average target across 3 active firms as of Nov 19, 2026 vs $1.86 current
Highest Target$7.00
Average Target$6.67
Lowest Target$6.00
Detailed analyst forecasts for SANA
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 3 of 3 active firms rate SANA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
SANA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.10
Range $-0.10 – $-0.10 · 1 analysts · -29% YoY
Next period, 1 analysts expect Sana Biotechnology Inc to earn $-0.10 a share (range $-0.10 – $-0.10), versus $-0.14 a year earlier. Full-year consensus is $-0.49, growing to $-0.44 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Sana Biotechnology Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SANA.
#1
Roger Song
Jefferies · Rank #122
Buy
$7.00+277.4% to target
Overall win rate
43%
+ Follow
#2
SS
Samantha Semenkow
Citigroup · Rank #333
Buy
$12.00+546.9% to target
Overall win rate
41%
+ Follow
#3
Reni J. Benjamin
JMP Securities · Rank #489
Buy
$8.00+331.3% to target
Overall win rate
29%
+ Follow
#4
Emily Bodnar
HC Wainwright & Co. · Rank #521
Buy
$7.00+277.4% to target
Overall win rate
24%
+ Follow
#5
MF
Marc Frahm
TD Cowen
Buy
No targeton SANA
Coverage
—
+ Follow
SANA stock forecast FAQ
What is SANA's average 12-month price target?+
The 3 active firms with a live target average $6.67 for Sana Biotechnology Inc over the next 12 months, ranging from a $7.00 high to a $6.00 low, as of Nov 19, 2026.
Is SANA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for SANA?+
The Street-high target is $7.00 (Wedbush), and the Street-low is $6.00 (B of A Securities). The average of all 3 active-firm targets is $6.67.
How many active Wall Street firms cover SANA?+
3 active firms have a recognized rating on Sana Biotechnology Inc as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering SANA?+
Among analysts who currently cover SANA, Roger Song of Jefferies has the strongest overall Quantellect track record (Rank #122). Their current call is Buy with a $7.00 target.
What is Sana Biotechnology Inc's projected EPS for next quarter?+
The consensus estimate is $-0.10 per share (range $-0.10 – $-0.10) across 1 analysts. Full-year EPS is projected at $-0.49, rising to $-0.44 the following year.
How much revenue is Sana Biotechnology Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading SANA lately?+
As of Nov 19, 2026, 3 of 3 active firms rate SANA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SANA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.